SPECTRUM PHARMACEUTICALS INC·4

May 29, 5:00 PM ET

Krassner Stuart Mitchell 4

4 · SPECTRUM PHARMACEUTICALS INC · Filed May 29, 2019

Insider Transaction Report

Form 4
Period: 2019-05-24
Transactions
  • Exercise/Conversion

    Common Stock, $0.001 par value

    2019-05-24$6.09/sh+5,071$30,88273,015 total
  • Sale

    Common Stock, $0.001 par value

    2019-05-24$7.94/sh5,071$40,26467,944 total
  • Exercise/Conversion

    Common Stock, $0.001 par value

    2019-05-28$6.09/sh+44,929$273,618112,873 total
  • Sale

    Common Stock, $0.001 par value

    2019-05-28$8.00/sh37,385$299,08075,488 total
  • Exercise/Conversion

    Stock Option Exercise (Right to Buy)

    2019-05-245,07144,929 total
    Exercise: $6.09From: 2012-06-26Exp: 2019-06-26Common Stock (5,071 underlying)
  • Exercise/Conversion

    Stock Option Exercise (Right to Buy)

    2019-05-2844,9290 total
    Exercise: $6.09From: 2012-06-26Exp: 2019-06-26Common Stock (44,929 underlying)
Footnotes (3)
  • [F1]This transaction represents an open market sale of a portion of the expiring stock options exercised on this Form 4 to satisfy the Reporting Person's payment of the exercise price and the taxes associated with such exercise.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.94 to $7.965, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.995 to $8.01, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION